This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Drug Design Data Resource | |
|---|---|
| Name | Drug Design Data Resource |
| Founded | 2010 |
| Type | Public database |
Drug Design Data Resource
The Drug Design Data Resource is an open scientific repository for biochemical, biophysical, and cheminformatic data intended to accelerate small‑molecule drug discovery. It aggregates experimental binding affinities, structural information, assay metadata, and curated ligand–target annotations to support computational chemistry, structural biology, and medicinal chemistry workflows. The platform is cited in workflows alongside major resources such as Protein Data Bank, PubChem, ChEMBL, DrugBank, and UniProt.
The Resource assembles diverse datasets including binding thermodynamics, kinetic rates, high‑throughput screening outcomes, and protein–ligand complex coordinates to enable benchmarking of algorithms used by groups affiliated with National Institutes of Health, Wellcome Trust, European Molecular Biology Laboratory, and industrial partners like Pfizer, Novartis, GlaxoSmithKline, and Roche. Its scope spans targets from model systems like HIV-1 protease, BACE1, and EGFR to emergent targets studied at institutions such as Massachusetts Institute of Technology, Stanford University, Harvard University, and University of Cambridge. The dataset is used in community challenges coordinated with organizations including Open Force Field Consortium, SAMPL challenge organizers, and the Drug Discovery Catalyst ecosystem.
Launched in the early 2010s following community calls for reproducible benchmarking after high‑profile collaborations among groups at University of California, San Francisco, Scripps Research Institute, and European Bioinformatics Institute, the Resource evolved from smaller curated collections maintained by academic consortia. Funding and governance have involved agencies and funders such as National Science Foundation, European Research Council, and philanthropic initiatives tied to Bill & Melinda Gates Foundation and Alfred P. Sloan Foundation. The platform’s growth mirrored advances in structural genomics projects from centers like Protein Structure Initiative and Structural Genomics Consortium and integrated standards influenced by efforts at RCSB PDB and GOLD (software) consortiums.
Data types include quantitative affinity measures (Kd, Ki, IC50), thermodynamic parameters derived from isothermal titration calorimetry studies often performed in laboratories at Columbia University, Yale University, and University of Oxford, and kinetic parameters such as kon/koff reported by groups at Max Planck Institute for Biophysics and ETH Zurich. Structural entries cross‑reference coordinates from Protein Data Bank and electron density or cryo‑EM maps produced by facilities like European Synchrotron Radiation Facility and EMBL-EBI. Small‑molecule representations link to identifiers in PubChem, ChEMBL, ZINC (database), and ChemSpider, and protein targets reference UniProt accessions and gene annotations correlated with gene protagonists at National Center for Biotechnology Information and ENSEMBL. Metadata schemas borrow from community standards established by FAIR Data Principles advocates, and ontologies developed by groups at Open Biological and Biomedical Ontology Foundry and Gene Ontology Consortium.
Users interact via web portals, programmatic APIs, and bulk downloadable snapshots, with client libraries used in computational pipelines at Google DeepMind, Microsoft Research, and IBM Research. Visualization and analysis tools integrate with molecular viewers such as PyMOL, UCSF Chimera, and NGL Viewer, while docking and free‑energy toolchains reference software like AutoDock Vina, GROMACS, AMBER, CHARMM, and OpenMM. The Resource supports submission workflows compatible with electronic lab notebook systems employed at GlaxoSmithKline and academic labs, and authentication/authorization follows models promoted by ORCID and ELIXIR infrastructure projects.
Researchers use the Resource to benchmark virtual screening campaigns, calibrate scoring functions in collaborations with teams from Johns Hopkins University and Imperial College London, and validate free‑energy perturbation methods pursued at University of California, Berkeley and Princeton University. It underpins academic‑industry consortia targeting neglected diseases coordinated with Medicines for Malaria Venture and translational programs at National Center for Advancing Translational Sciences. Use cases include hit‑to‑lead optimization, off‑target profiling comparing entries to data from ToxCast, and retrospective analyses informing patent strategies at firms like Merck & Co. and AstraZeneca.
Governance is typically stewarded by a board comprising representatives from universities (e.g., University of Michigan, University of Toronto), non‑profit organizations (e.g., Structural Genomics Consortium), and industry partners including Bayer and Eli Lilly and Company. Data curation follows community guidelines influenced by workshops convened at Cold Spring Harbor Laboratory, Gordon Research Conferences, and policy forums at World Health Organization. Contributor recognition mechanisms align with citation practices endorsed by Nature Publishing Group and Science (journal) editorial standards, and data provenance is tracked to laboratories and principal investigators registered with ORCID.
Challenges include heterogeneity of assay protocols reported across laboratories such as Broad Institute and EMBL‑EBI affiliates, inconsistency in small‑molecule stereochemistry annotations linked to records in PubChem and ChEMBL, and gaps in kinetic datasets compared with thermodynamic coverage. Legal and licensing considerations interact with intellectual property regimes from patent offices like United States Patent and Trademark Office and European Patent Office, complicating integration of proprietary datasets from companies such as Bristol-Myers Squibb. Ongoing work addresses data harmonization, standardization of metadata schemas promoted by FAIR Data Principles, and fostering sustainable funding models with stakeholders including Wellcome Trust and national funders.
Category:Open science resources